drugset

Drugs / Human umbilical cord tissue-derived mesenchymal stem cells

Follow last change Oct 2019 re-read 2 minutes ago

Human umbilical cord tissue-derived mesenchymal stem cells

also known as UC-MSC

Developed for: spinal cord injury · osteoarthritis, knee
Investigated by: Translational Biosciences

Trials 1 · a red edge is where a trial was stopped

today NCT02237547 · Ph 1/2

2015201620172018201920202021202220232024202520262027

Phase	Registry id	Dates	Indication	Sponsor	Status	Outcome
Phase 1/2	NCT02237547	Sep 2014 → Jan 2019	spinal cord injury	Translational Biosciences	Withdrawn	No outcome recorded

Also used as a comparator or background therapy in 1 trial

Phase	Registry id	Dates	Indication	Sponsor	Status	Outcome
Phase 1/2	NCT02237846 Comparator	Sep 2014 → Nov 2018	osteoarthritis, knee	Translational Biosciences	Withdrawn	No outcome recorded

Evidence & citations 5 cited values

Every value below carries the sentence it was read from. 2 sources stand behind the page.

Field	Value	Cited text
Known as	human umbilical cord tissue-derived mesenchymal stem cells	ClinicalTrials.gov intervention name — accepted as the source's own label NCT02237547 ↗ 1 NCT02237846 ↗
Known as	UC-MSC	“Human Umbilical Cord-derived Mesenchymal Stem Cells (UC-MSC) and Bone Marrow Mononuclear Cells (BMMC) from the patient injected into the spinal fluid intrathecally and injected...” NCT02237547 ↗
Modality	Cell therapy	“Human umbilical cord tissue-derived mesenchymal stem cells” NCT02237846 ↗
Route	Intrathecal	“administered intrathecally and intravenously multiple times over the course of one month” NCT02237547 ↗
Route	Intravenous	“administered intrathecally and intravenously multiple times over the course of one month” NCT02237547 ↗